Intra-Cellular Therapies
ITCI
$73.38
Share price
-0.84%
Change (1 day)
17.89%
Change (1 year)
Categories
Intra-Cellular Therapies (ITCI) - Cash on Hand
Cash on Hand as of December 2023 : $0.49 B
According to Intra-Cellular Therapies's latest financial reports the company has $0.49 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Intra-Cellular Therapies - Cash on Hand chart (from 2013 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $0.49 B | -15.87% |
| 2022-12-31 | $0.59 B | 43.55% |
| 2021-12-31 | $0.41 B | -37.28% |
| 2020-12-31 | $0.65 B | 193.49% |
| 2019-12-31 | $0.22 B | -35.54% |
| 2018-12-31 | $0.34 B | -25.15% |
| 2017-12-31 | $0.46 B | 20.89% |
| 2016-12-31 | $0.38 B | -19.17% |
| 2015-12-31 | $0.47 B | 266.54% |
| 2014-12-31 | $0.12 B | 248.97% |
| 2013-12-31 | $37.15 M | 94.04% |
| 2013-03-31 | $0 M | |
| 2012-12-31 | $19.14 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | $0.59 B | 19.24% | 🇺🇸 USA |
 MediciNova MNOV | $50.99 M | -89.76% | 🇺🇸 USA |
 Curis CRIS | $56.33 M | -88.69% | 🇺🇸 USA |